New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 12, 2014
12:44 EDTEPL, WLH, PGR, PAY, PHM, EXXI, GERN, TOLOn The Fly: Midday Wrap
Stocks on Wall Street were mixed at midday, with the Nasdaq the lone major index trading in positive territory. Stocks trading in New York began the session in the red, taking their lead from overseas markets which were weaker on global growth concerns. The market drifted off its lows and all three major averages made it back to positive ground, though the Dow and S&P have slipped back below yesterday's closing levels. ECONOMIC EVENTS: In the U.S., MBA's mortgage applications index fell 2.1% last week. The federal budget for February is scheduled to be reported at 2:00 pm ET. In Asia, Reuters said overnight that China's central bank is prepared to cut the amount of cash that banks must keep as reserves if economic growth slows further. COMPANY NEWS: Shares of a number of homebuilders sunk after Credit Suisse downgraded three companies in the sector, saying that the spring selling season looks set to be "underwhelming." Credit Suisse analyst Daniel Oppenheim wrote that the firm's survey of real estate agents last month indicates that demand for housing was weak. Buyer traffic fell compared with January and February 2013, the analyst stated, adding that homebuilders' stocks generally reflect optimistic outlooks. As a result, he downgraded three names in the sector - Toll Brothers (TOL), PulteGroup (PHM), and William Lyon Homes (WLH) - to Neutral from Outperform. Near midday, Pulte shares were down over 2%, Toll slid almost 2% and William Lyon fell 1%. MAJOR MOVERS: Among the notable gainers was electronic payment solution provider VeriFone Systems (PAY), which hit a new 52-week high earlier in the session and was up about 9% near midday after the company's first quarter results topped expectations. Also higher was EPL Oil & Gas (EPL), which jumped 30% after the company agreed to be acquired by Energy XXI (EXXI) in a deal that will see stockholders receive a consideration valued at $39.00 per EPL share. Shares of Energy XXI slipped 6% following the deal announcement. Among the other noteworthy losers was insurer Progressive (underwhelming), which fell more than 3% after reporting its net premiums written rose 3% to $1.54B in February. Also lower were shares of Geron (GERN), which plunged over 62% and was downgraded to Neutral from Overweight at Piper Jaffray after the FDA put a full clinical hold for all company-sponsored imetelstat studies. INDEXES: Near midday, the Dow was down 36.20, or 0.22%, to 16,315.05, the Nasdaq was up 3.14, or 0.07%, to 4,310.33, and the S&P 500 was down 3.89, or 0.21%, to 1,863.74.
News For TOL;PHM;WLH;GERN;PAY;EPL;EXXI;PGR From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
November 26, 2014
14:40 EDTTOLToll Brothers volatility low into Q4 and outlook
Toll Brothers December weekly call option implied volatility is at 20, December, January and, March is at 24; compared to its 26-week average of 26 according to Track Data, suggesting decreasing price movement into the expected release of Q4 results on December 10.
November 21, 2014
10:50 EDTGERNGeron November volatility at low end of two-year range as shares trend higher
Geron December call option implied volatility is at 86, January is at 88, March is at 78; compared to its 26-week average of 106 according to Track Data, suggesting decreasing price risk.
November 19, 2014
11:42 EDTEXXIEnergy XXI director discloses 10K share purchase at $6.63
Subscribe for More Information
November 18, 2014
09:24 EDTWLHWilliam Lyon Homes upgraded to Outperform from Neutral at Credit Suisse
Subscribe for More Information
06:10 EDTWLHWilliam Lyon Homes announces pricing of tangible equity units
Subscribe for More Information
November 17, 2014
16:24 EDTWLHOn The Fly: Closing Wrap
Stocks on Wall Street were quiet and traded in a fairly narrow range for their sixth straight session, despite a "merger Monday" that saw over $100B in deals announced. The Dow and S&P, which began the week near record levels, passed back and forth across the flat line several times during the day, though the Nasdaq weakened early in the session and never really recovered. ECONOMIC EVENTS: In the U.S., industrial production fell 0.1% in October, missing expectations for it to have risen 0.2% from the prior month. October capacity utilization came in at 78.9%, which fell short of the expected 79.3% rate. The Empire State manufacturing index, which reflects manufacturing activity in the New York region, rose 4 points to 10.2 in November, which was generally in-line with the consensus forecast. In Asia, Japan's GDP unexpectedly shrank an annualized 1.6% last quarter, missing projections for a 2.2% gain and sinking its economy into a recession. COMPANY NEWS: Actavis (ACT) gained $4.17, or 1.71%, to $247.94 after confirming that it agreed to acquire Allergan (AGN) for a combination of $129.22 in cash and 0.3683 Actavis shares valued at approximately $66B, or $219 per Allergan share. Valeant Pharmaceuticals (VRX), which had been in a contentious fight to buy Allergan, commented that it "cannot justify to its own shareholders" paying a price of $219 or more per share for the Botox maker, whose stock rose $10.55, or 5.31%, to $209.20... Halliburton (HAL), conversely, fell $5.85, or 10.62%, to $49.23 after it agreed to acquire Baker Hughes (BHI) in a stock and cash transaction valued at $78.62 per Baker Hughes share, representing an enterprise value of $38B. When the deal talks were first reported by The Wall Street Journal last week, antitrust concerns were highlighted by analysts, but Halliburton said it had agreed to divest businesses that generate up to $7.5B in revenues, if required by regulators, and agreed to pay a fee of $3.5B if the transaction terminates due to a failure to obtain required approvals. Baker Hughes rose $5.34, or 8.92%, to $65.23 after the deal was announced. MAJOR MOVERS: Among the notable gainers was Celldex Therapeutics (CLDX), which advanced $4.09, or 28.88%, to $18.25 after the company reported it saw a statistically significant overall survival benefit, along with an increase in clinically meaningful tumor shrinkage, in a sub-group of its study of a drug to treat a specific type of brain tumor. Also higher was Amicus Therapeutics (FOLD), which rose $1.01, or 17.75%, to $6.70 after the company announced additional data on secondary endpoints from its second Phase 3 study of its treatment for Fabry disease. Among the noteworthy losers was William Lyon Homes (WLH), which fell $3.52, or 15.53%, to $19.14 after the company announced that it intends to offer, subject to market and other conditions, 1M tangible equity units, which will consist of a prepaid stock purchase contract and an amortizing note. Also lower were shares of DreamWorks (DWA), which dropped $3.71, or 14.26%, to $22.31 after multiple media outlets reported that talks about a takeover of the company by Hasbro (HAS) had ended. INDEXES: The Dow gained 13.01, or 0.07%, to 17,647.75, the Nasdaq lost 17.54, or 0.37%, to 4,671.00, and the S&P 500 added 1.50, or 0.07%, to 2,041.32.
11:06 EDTGERNLeerink biotech analysts hold an analyst/industry conference call
Subscribe for More Information
07:35 EDTWLHWilliam Lyon Homes files to sell tangible equity units
Subscribe for More Information
November 14, 2014
16:21 EDTGERNOn The Fly: Closing Wrap
Subscribe for More Information
12:58 EDTGERNOn The Fly: Midday Wrap
Subscribe for More Information
12:48 EDTGERNGeron November volatility up on strategic collaboration with Janssen Biotech
Subscribe for More Information
10:00 EDTGERNOn The Fly: Analyst Upgrade Summary
Subscribe for More Information
09:16 EDTGERNOn The Fly: Pre-market Movers
Subscribe for More Information
07:32 EDTEXXIHayman Capital gives quarterly update on stakes
Subscribe for More Information
07:12 EDTGERNGeron upgraded to Overweight from Neutral at Piper Jaffray
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use